A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema

Trial Profile

A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms FAME
  • Sponsors Alimera Sciences
  • Most Recent Events

    • 09 Aug 2017 According to an Alimera Sciences media release, data will be presented at the 2017 American Society of Retinal Specialists (ASRS) Annual Meeting.
    • 16 Nov 2015 According to an Alimera Sciences media release, results of this study will be presented at the American Academy of Ophthalmology Annual Meeting 2015.
    • 16 Nov 2015 Results published in an Alimera Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top